Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

v3.23.3
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]  
Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model Under the TeraImmune 2019 Plan, the fair value of the options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions:

 

 

 

September 30,

 

 

 

2023

 

Expected option life

 

5.6 years

 

Expected volatility

 

105%

 

Risk-free interest rate

 

4.38%

 

Expected dividend yield

 

 

—

 
Summary of Stock Option Activity

The following table summarizes Baudax Bio stock option activity during the nine months ended September 30, 2023:

 

 

 

Number of
shares

 

 

Weighted
average
exercise
price

 

 

Weighted
average
remaining
contractual life

Balance, December 31, 2022

 

 

1,939

 

 

$

3,509.06

 

 

6.5 years

Expired/forfeited/cancelled

 

 

(402

)

 

$

3,891.09

 

 

 

Balance, September 30, 2023

 

 

1,537

 

 

$

3,412.09

 

 

7.4 years

Vested

 

 

1,268

 

 

$

3,523.09

 

 

7.3 years

Vested and expected to vest

 

 

1,537

 

 

$

3,412.09

 

 

7.4 years
Summary of RSUs Activity

The following table summarizes Baudax Bio RSUs activity during the nine months ended September 30, 2023:

 

 

 

Number of
shares

 

 

Weighted
average
grant date
fair value

 

Balance, December 31, 2022

 

 

10,611

 

 

$

88.19

 

Granted

 

 

—

 

 

 

—

 

Vested and settled

 

 

(7,558

)

 

 

3.41

 

Expired/forfeited/cancelled

 

 

(386

)

 

 

1,318.71

 

Balance, September 30, 2023

 

 

2,667

 

 

$

150.34

 

Expected to vest

 

 

2,667

 

 

 

 
TeraImmune 2019 Equity Plan  
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]  
Summary of Stock Option Activity

The following table summarizes the stock option activity during the nine months ended September 30, 2023:

 

 

 

Number of
shares

 

 

Weighted
average
exercise
price

 

 

Weighted
average
remaining
contractual life

 

Balance, December 31, 2022

 

 

—

 

 

$

—

 

 

 

—

 

Granted

 

 

973,287

 

 

$

2.37

 

 

5.6 years

 

Expired/forfeited/cancelled

 

 

—

 

 

$

—

 

 

 

 

Balance, September 30, 2023

 

 

973,287

 

 

$

2.37

 

 

5.4 years

 

Vested

 

 

275,370

 

 

$

2.22

 

 

4.1 years

 

Vested and expected to vest

 

 

973,287

 

 

$

2.37

 

 

5.4 years